225 related articles for article (PubMed ID: 10736497)
1. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia.
Boyle P; Robertson C; Lowe F; Roehrborn C
Urology; 2000 Apr; 55(4):533-9. PubMed ID: 10736497
[TBL] [Abstract][Full Text] [Related]
2. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
Boyle P; Robertson C; Lowe F; Roehrborn C
BJU Int; 2004 Apr; 93(6):751-6. PubMed ID: 15049985
[TBL] [Abstract][Full Text] [Related]
3. Serenoa repens for benign prostatic hyperplasia.
Tacklind J; MacDonald R; Rutks I; Wilt TJ
Cochrane Database Syst Rev; 2009 Apr; (2):CD001423. PubMed ID: 19370565
[TBL] [Abstract][Full Text] [Related]
4. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Plosker GL; Brogden RN
Drugs Aging; 1996 Nov; 9(5):379-95. PubMed ID: 8922564
[TBL] [Abstract][Full Text] [Related]
5. Serenoa repens for benign prostatic hyperplasia.
Tacklind J; Macdonald R; Rutks I; Stanke JU; Wilt TJ
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD001423. PubMed ID: 23235581
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
Zlotta AR; Teillac P; Raynaud JP; Schulman CC
Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
[TBL] [Abstract][Full Text] [Related]
9. Serenoa repens for benign prostatic hyperplasia.
Wilt T; Ishani A; Mac Donald R
Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
[TBL] [Abstract][Full Text] [Related]
10. Phytotherapy for benign prostatic hyperplasia.
Wilt TJ; Ishani A; Rutks I; MacDonald R
Public Health Nutr; 2000 Dec; 3(4A):459-72. PubMed ID: 11276294
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Novara G; Giannarini G; Alcaraz A; Cózar-Olmo JM; Descazeaud A; Montorsi F; Ficarra V
Eur Urol Focus; 2016 Dec; 2(5):553-561. PubMed ID: 28723522
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
[TBL] [Abstract][Full Text] [Related]
13. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
MacDonald R; Tacklind JW; Rutks I; Wilt TJ
BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
[TBL] [Abstract][Full Text] [Related]
14. The value of permixon in benign prostatic hypertrophy.
Reece Smith H; Memon A; Smart CJ; Dewbury K
Br J Urol; 1986 Feb; 58(1):36-40. PubMed ID: 2418902
[TBL] [Abstract][Full Text] [Related]
15. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
Buck AC
J Urol; 2004 Nov; 172(5 Pt 1):1792-9. PubMed ID: 15540722
[TBL] [Abstract][Full Text] [Related]
16. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
[TBL] [Abstract][Full Text] [Related]
17. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.
Wilt TJ; Ishani A; Stark G; MacDonald R; Lau J; Mulrow C
JAMA; 1998 Nov; 280(18):1604-9. PubMed ID: 9820264
[TBL] [Abstract][Full Text] [Related]
18. Hexanic Extract of Serenoa repens (Permixon
Blair HA
Drugs Aging; 2022 Mar; 39(3):235-243. PubMed ID: 35237936
[TBL] [Abstract][Full Text] [Related]
19. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia.
Pytel YA; Vinarov A; Lopatkin N; Sivkov A; Gorilovsky L; Raynaud JP
Adv Ther; 2002; 19(6):297-306. PubMed ID: 12665050
[TBL] [Abstract][Full Text] [Related]
20. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
Carraro JC; Raynaud JP; Koch G; Chisholm GD; Di Silverio F; Teillac P; Da Silva FC; Cauquil J; Chopin DK; Hamdy FC; Hanus M; Hauri D; Kalinteris A; Marencak J; Perier A; Perrin P
Prostate; 1996 Oct; 29(4):231-40; discussion 241-2. PubMed ID: 8876706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
